Ventyx Biosciences Inc (VTYX) Stock Price, Quote & News

Company Profile

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like recept...

Industry: Biotechnology

Sector: Healthcare

Phone: 760 593 4832

Website: ventyxbio.com

Address:

12790 El Camino Real, Suite 200, San Diego, United States

TrenchTrader Dec. 25 at 9:02 AM

$VTYX Strategic positioning matters less than consistent throughput, since capital markets reward discipline over expansion for its own sake. Shortfalls would likely reprice expectations quickly.

0 · Reply

BillionerOfKing Dec. 25 at 2:41 AM

$VTYX Current Stock Price: $9.18 Contracts to trade: $10 VTYX Jan 16 2026 Call Entry: $0.15 Exit: $0.21 ROI: 37% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

MoneyGroupLLC Dec. 24 at 1:39 PM

Enter: $VTYX Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.70 - $0.73 Sell Price: $1.15 Profit : +65% (Turn every $1 into $1.65) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Goatedinvestor Dec. 23 at 11:41 PM

$VTYX Sanofi has first bid , but NVO will definitely also be looking at a way to keep oral sema competitive , expect some back in forth bids between those companies here

0 · Reply

Kabita84 Dec. 23 at 2:11 AM

$VTYX people with patience made money here already..promising company

0 · Reply

MoneyGroupLLC Dec. 22 at 7:44 PM

Enter: $VTYX Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.70 - $0.90 Sell Price: $1.46 Profit : +108% (Turn every $1 into $2.08) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

1iquid Dec. 22 at 3:17 AM

💎 Liquid® Live Actionable Trade Asset: $VTYX Contracts: $VTYX June 18, 2026 $10 Calls Scale in: $2.14- $2.61 Scale out: $8.31-$14.25 Profit Potential : 290% ROI Blended Join 💎 Here: https://1iquid.com

0 · Reply

Doozio Dec. 21 at 4:36 PM

$VTYX all the way up da Roger while $TVTX is nice n tight with huckleberries @ da $$$. It was always ENTA 🐒🍌🧠⏰♾️

0 · Reply

Daniels_ Dec. 20 at 9:08 PM

$VTYX biotech with big gap history, tape only favors you after a hard base build and volume breakout not in random bounce mode

0 · Reply

MoneyGroupLLC Dec. 20 at 6:40 PM

Enter: $VTYX Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.65 - $0.90 Sell Price: $1.14 Profit : +76% (Turn every $1 into $1.76) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Ventyx Provides Clinical and Corporate Updates

Dec 1, 2025, 7:02 AM EST - 24 days ago

Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 7:02 AM EST - 5 weeks ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 4:02 PM EST - 6 weeks ago

Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Oct 24, 2025, 2:17 AM EDT - 2 months ago

Ventyx Biosciences, Inc. (VTYX) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors Transcript

Oct 22, 2025, 4:02 PM EDT - 2 months ago

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Aug 27, 2025, 7:02 AM EDT - 4 months ago

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Aug 7, 2025, 4:05 PM EDT - 5 months ago

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Jun 17, 2025, 7:00 AM EDT - 6 months ago

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

May 28, 2025, 8:00 AM EDT - 7 months ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

May 8, 2025, 4:01 PM EDT - 8 months ago

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Apr 1, 2025, 7:00 AM EDT - 9 months ago

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Feb 27, 2025, 4:05 PM EST - 10 months ago

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Feb 18, 2025, 8:00 AM EST - 11 months ago

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Feb 5, 2025, 8:00 AM EST - 11 months ago

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 14, 2025, 8:00 AM EST - 1 year ago

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Nov 4, 2024, 10:32 AM EST - 1 year ago

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Sep 23, 2024, 11:13 AM EDT - 1 year ago

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences

SNY

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Departure of Chief Financial Officer

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Jul 29, 2024, 2:31 PM EDT - 1 year ago

Dow Edges Lower; Ventyx Biosciences Shares Plummet

Jul 29, 2024, 11:03 AM EDT - 1 year ago

Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further

Jun 24, 2024, 6:00 AM EDT - 1 year ago

VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details

Jun 21, 2024, 4:15 PM EDT - 1 year ago

VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details

Jun 20, 2024, 7:20 AM EDT - 1 year ago

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

Jun 19, 2024, 4:20 PM EDT - 1 year ago

VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses

Jun 18, 2024, 3:42 PM EDT - 1 year ago

VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses

Jun 17, 2024, 6:32 AM EDT - 1 year ago

VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 13, 2024, 4:06 PM EDT - 1 year ago

BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 13, 2024, 7:13 AM EDT - 1 year ago

VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm

Jun 12, 2024, 4:04 PM EDT - 1 year ago

STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading

Jun 11, 2024, 3:37 PM EDT - 1 year ago

VENTYX STOCK NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors

Jun 11, 2024, 6:41 AM EDT - 1 year ago

VENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's Board

Jun 8, 2024, 5:24 AM EDT - 1 year ago

VENTYX NEWS NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Urged to Contact BFA Law about the Investigation into the Company's Board of Directors

Jun 5, 2024, 4:01 PM EDT - 1 year ago

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

May 16, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

May 11, 2024, 1:58 PM EDT - 1 year ago

Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 1 year ago

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

TrenchTrader Dec. 25 at 9:02 AM

$VTYX Strategic positioning matters less than consistent throughput, since capital markets reward discipline over expansion for its own sake. Shortfalls would likely reprice expectations quickly.

0 · Reply

BillionerOfKing Dec. 25 at 2:41 AM

0 · Reply

MoneyGroupLLC Dec. 24 at 1:39 PM

0 · Reply

Goatedinvestor Dec. 23 at 11:41 PM

$VTYX Sanofi has first bid , but NVO will definitely also be looking at a way to keep oral sema competitive , expect some back in forth bids between those companies here

0 · Reply

Kabita84 Dec. 23 at 2:11 AM

$VTYX people with patience made money here already..promising company

0 · Reply

MoneyGroupLLC Dec. 22 at 7:44 PM

0 · Reply

1iquid Dec. 22 at 3:17 AM

0 · Reply

Doozio Dec. 21 at 4:36 PM

$VTYX all the way up da Roger while $TVTX is nice n tight with huckleberries @ da $$$. It was always ENTA 🐒🍌🧠⏰♾️

0 · Reply

Daniels_ Dec. 20 at 9:08 PM

$VTYX biotech with big gap history, tape only favors you after a hard base build and volume breakout not in random bounce mode

0 · Reply

MoneyGroupLLC Dec. 20 at 6:40 PM

0 · Reply

knightbuster123 Dec. 19 at 8:54 PM

$VTYX Power Day! Swinging!

0 · Reply

SimpleWinningSetups Dec. 19 at 8:43 PM

Hedge Alert Live - Protect Your Portfolio Contract: $VTYX $7.50 Put · JAN 16, 2026 Exp Entry Price: $0.65 - $0.68 Exit Price Target: $0.90 Profit Margin: +39% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

MoneyGroupLLC Dec. 19 at 6:14 PM

Enter: $VTYX Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.30 - $0.45 Sell Price: $0.53 Profit : +76% (Turn every $1 into $1.76) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Hi_High Dec. 19 at 5:49 PM

$VTYX I bought $7.75. Good!

0 · Reply

Timah73 Dec. 19 at 11:11 AM

$VTYX 😳

0 · Reply

Joe_088 Dec. 19 at 9:08 AM

$VTYX 👀

0 · Reply

RamboYuh27 Dec. 19 at 3:19 AM

$VTYX in at $1.66. Let’s run

0 · Reply

Agafon12 Dec. 18 at 6:44 PM

$VTYX April 1, 2025: Ventyx Biosciences expands its Scientific Advisory Board (SAB) with renowned NLRP3 experts and leading specialists in neurodegenerative and cardiometabolic diseases — and then, 3–5 months later, we get strong data for VTX3232. On December 2, 2025, Ventyx officially announced that it added two top experts to its advisory board in the context of a Phase 2 update for VTX2735: Mark McKenna (Strategic Advisor) and Peter Libby, MD (Clinical Advisor). Now think about what happens next.

0 · Reply

MoneyGroupLLC Dec. 18 at 5:44 PM

Enter: $VTYX Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.30 - $0.60 Sell Price: $0.49 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Dr_Monkeybreath Dec. 18 at 2:25 PM

$VTYX 👀 $GTBP epic rebound potential in next few weeks. 🤑

0 · Reply

Elevate1 Dec. 18 at 12:41 PM

$VTYX I still believe that nlrp3 inhibitors are the natural compliment to Glp-1 and glp agonists as well as the new triple G pill. The glp-1’s attack inflammation at the start of the antioxidant chain but as 3232 does it deals with the chronic inflammation’s activation. It appears that VTYX can make them selective like to neuronal, liver and cardo(2735). This makes them an indispensable company to associate with. Myself and SOD2 enthusiast have published several research papers describing this interaction. VTYX will be taken out in my opinion and soon. sNY cannot wait any longer since they just lost a $1 billion muscular dystrophy drug . They need 3232! So why not make the move to snag this company any day! I am long and will trade at will

1 · Reply

Viktor4o Dec. 17 at 9:05 PM

$VTYX Something is brewing 🤔

0 · Reply

Market Cap	647.23M
Revenue (ttm)	0.00
Net Income (ttm)	-135.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	593,300
Avg Vol	5,111,206
Day's Range	N/A - N/A
Shares Out	71.36M
Stochastic %K	82%
Beta	1.22
Analysts	Strong Sell
Price Target	$15.14